Related Experiment Videos

Identification of four novel splice site mutations in the ornithine transcarbamylase gene

E Oppliger Leibundgut1, B Wermuth, J P Colombo

  • 1Department of Clinical Chemistry, Inselspital, University of Berne, Switzerland.

Human Genetics
|February 1, 1996
PubMed

Insights

Four new mutations in the ornithine transcarbamylase (OTC) gene were identified, causing severe urea cycle disorder. These genetic changes affect crucial splice sites, leading to early-onset disease in infants.

Area of Science:

  • Genetics
  • Biochemistry
  • Pediatrics

Background:

  • Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder.
  • It exhibits X-linked inheritance with a high rate of new mutations.

Purpose of the Study:

  • To identify novel mutations causing OTC deficiency.
  • To investigate the impact of these mutations on disease presentation and severity.

Main Methods:

  • Polymerase chain reaction (PCR) amplification of OTC gene exons and adjacent introns.
  • Direct sequencing of amplified DNA segments.

Main Results:

  • Four new mutations affecting donor splice sites in introns 2, 5, 6, and 8 of the OTC gene were identified.
  • These mutations were associated with severe neonatal or early-onset hyperammonemia in three male and one female patients.
  • Specific mutations included G to A (intron 2), G to C (intron 5), and G to T (introns 6 and 8) exchanges.

Conclusions:

  • The identified splice site mutations disrupt proper mRNA splicing, leading to aberrant OTC gene products.
  • These mutations result in severe clinical manifestations of OTC deficiency, often with fatal outcomes in early infancy.

Related Concept Videos